- Conditions
- Prostate Cancer
- Interventions
- lapatinib ditosylate
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Liver Cancer
- Interventions
- cetuximab, capecitabine, oxaliplatin
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Olaparib, Ramucirumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 32
- States / cities
- Corona, California • Duarte, California • Lancaster, California + 24 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- docetaxel, irinotecan hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
- Conditions
- Gastric Adenocarcinoma, GastroEsophageal Cancer
- Interventions
- Cabozantinib, Pembrolizumab
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
- Interventions
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
- Interventions
- ziv-aflibercept, pharmacological study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Interventions
- exatecan mesylate
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 5
- States / cities
- Denver, Colorado • New York, New York • Dallas, Texas + 2 more
- Conditions
- Mucinous Gastrointestinal Adenocarcinoma
- Interventions
- cetuximab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- New York, New York • Cincinnati, Ohio
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- irofulven
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 3
- States / cities
- Omaha, Nebraska • Fort Sam Houston, Texas • San Antonio, Texas
- Conditions
- Low Grade Serous Carcinoma
- Interventions
- Ribociclib, Letrozole
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 27
- States / cities
- San Francisco, California • Gainesville, Florida • Tampa, Florida + 19 more
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Pancreatic Ductal Adenocarcinoma, Progesterone Receptor Negative, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Lymphoma, Refractory Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
- Interventions
- Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- cixutumumab, computed tomography, contrast-enhanced magnetic resonance imaging
- Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, cyclophosphamide, mitoxantrone hydrochloride, paclitaxel, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Up to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 41 more
- Conditions
- Liver Cancer, Metastatic Cancer
- Interventions
- cisplatin, doxorubicin, mitomycin, embolization
- Drug · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 37
- States / cities
- Fort Collins, Colorado • Jacksonville, Florida • Atlanta, Georgia + 18 more
- Conditions
- Kidney Cancer
- Interventions
- tinzaparin sodium
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Lebanon, New Hampshire • Burlington, Vermont
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- enzalutamide, abiraterone, prednisone
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 527
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 382 more
- Conditions
- Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
- Interventions
- darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 64
- States / cities
- Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Resonance Imaging, Biopsy, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV, Recurrent Lung Adenocarcinoma, Recurrent Lung Cancer
- Interventions
- Trametinib, Erlotinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- triapine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas